[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-heart-disease-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-heart-disease-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100653992","phase-4-release---reconsidering-long-term-aspirin-in-the-elderly-patients-with-stable-ischemic-heart-disease-a-randomized-non-inferiority-trial-100653992",false,"NCT07795398","DAN-RELEASE - Reconsidering Long-Term Aspirin in the Elderly Patients With Stable Ischemic Heart Disease","The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease","DAN-RELEASE","Inclusion Criteria:\n\n* Age ≥65 years at randomization\n* Ischemic heart disease (IHD) with index event (myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)) \\>2 years previously\n* Since index event free from ischemic cardiovascular events (MI, ischemic stroke, or transitory ischemic attack) or any coronary revascularization procedure (PCI\u002FCABG)\n* Currently treated with low dose aspirin (≤150 mg daily)\n\nExclusion Criteria:\n\n* History of ischemic stroke\n* Active treatment with or indication for anti-coagulant or P2Y12-inhibitor therapy\n* Indication for antiplatelet treatment other than secondary prevention of IHD according to treating physician (i.e. haematological diseases, peripheral artery disease)\n* Any revascularization procedure for peripheral artery disease\n* Any history of stent thrombosis or stenting of the left main coronary artery\n* Other contraindications to aspirin discontinuation according to treating physician\n* Not being able to understand Danish","ALL","65 Years",{"count":20,"type":21},7000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","DAN-RELEASE is a national, randomized, registry-based trial including 7,000 participants in Denmark. The trial aims to determine whether discontinuation of long-term aspirin therapy is non-inferior to continued aspirin therapy in older adults with stable ischemic heart disease.\n\nLong-term aspirin therapy is recommended for patients with established ischemic heart disease. However, among clinically stable patients years after percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or myocardial infarction (MI), the evidence supporting lifelong aspirin therapy is limited. At the same time, the risk of serious bleeding increases with age.\n\nDAN-RELEASE will therefore compare aspirin discontinuation with continued aspirin therapy in adults aged 65 years or older with stable ischemic heart disease who have remained free from ischemic events for at least two years. The trial will assess whether discontinuing aspirin is non-inferior to continued treatment with respect to cardiovascular and bleeding outcomes.",[27,28,29,30,31,32,33,34,35],"Ischemic Heart Disease","Ischemic Heart Disease Chronic","Chronic Coronary Syndrome","Myocardial Infarction","Percutaneous Coronary Intervention","Coronary Artery Bypass Graft","Aspirin","Aspirin Causing Adverse Effects in Therapeutic Use","Non-inferiority Trial",[37,38],"Ischemic heart disease","Chronic coronary syndrome","RECRUITING","2026-10-01",{"date":42,"type":43},"2026-10-05","ACTUAL",{"date":45,"type":43},"2026-09-30",{"date":47,"type":21},"2029-10",{"name":49,"class":50},"Odense University Hospital","OTHER",2]